Skip to main content

Research Repository

Advanced Search

Outputs (11)

Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction‐associated steatotic liver disease but is not altered by 6 weeks of exercise training (2024)
Journal Article
Willis, S. A., Malaikah, S., Bawden, S. J., Sherry, A. P., Sargeant, J. A., Coull, N. A., Bradley, C. R., Rowlands, A., Naim, I., Ennequin, G., Yates, T., Waheed, G., Gowland, P., Stensel, D. J., Webb, D. R., Davies, M. J., Aithal, G. P., & King, J. A. (2024). Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction‐associated steatotic liver disease but is not altered by 6 weeks of exercise training. Diabetes, Obesity and Metabolism, 26(9), 4030-4042. https://doi.org/10.1111/dom.15755

Aims: To examine the impact of impaired glycaemic regulation (IGR) and exercise training on hepatic lipid composition in men with metabolic dysfunction‐associated steatotic liver disease (MASLD). Materials and Methods: In Part A (cross‐sectional desi... Read More about Greater hepatic lipid saturation is associated with impaired glycaemic regulation in men with metabolic dysfunction‐associated steatotic liver disease but is not altered by 6 weeks of exercise training.

Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases (2024)
Journal Article
Fuller, A., Hancox, J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Maxwell, J. R., Bingham, S., Vedhara, K., & Abhishek, A. (2025). Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases. Rheumatology, 64(3), 969-975. https://doi.org/10.1093/rheumatology/keae175

Objective
To explore the acceptability of an individualized risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s).

Methods
Ad... Read More about Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., Stevenson, M. D., Nakafero, G., & Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2023)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Riley, R. D., Warren, R. B., & Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation (2023)
Journal Article
Nakafero, G., Card, T., Grainge, M. J., Williams, H. C., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Stevenson, M. D., Riley, R. D., & Abhishek, A. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64, Article 102213. https://doi.org/10.1016/j.eclinm.2023.102213

Background: Patients established on thiopurines (e.g., azathioprine) are recommended to undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity. These side-effects are uncommon during long-term treatment. We deve... Read More about Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation.

Application and Extension of the Alcohol Recovery Narratives Conceptual Framework (2023)
Journal Article
Subhani, M., Talat, U., Knight, H., Morling, J. R., Jones, K. A., Aithal, G. P., Ryder, S. D., & Rennick-Egglestone, S. (2023). Application and Extension of the Alcohol Recovery Narratives Conceptual Framework. Qualitative Health Research, 33(13), 1203-1217. https://doi.org/10.1177/10497323231197384

Recovery narratives are personal stories of health problems and recovery. A systematic review proposed a conceptual framework characterising alcohol misuse recovery narratives, consisting of eight principal dimensions, each with types and subtypes. T... Read More about Application and Extension of the Alcohol Recovery Narratives Conceptual Framework.

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK (2023)
Journal Article
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., Fox, C. P., Mallen, C. D., van der Windt, D. A., Stevenson, M. D., Riley, R. D., & Abhishek, A. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381, Article e074678. https://doi.org/10.1136/bmj-2022-074678

OBJECTIVE: To develop and validate a prognostic model to inform risk stratified decisions on frequency of monitoring blood tests during long term methotrexate treatment. DESIGN: Retrospective cohort study. SETTING: Electronic health records within th... Read More about Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., Jordan, K. M., Ala, A., Hutchinson, D., Aspinall, R. J., Murphy, R., & Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study (2007)
Journal Article
Jackson, H., Solaymani-Dodaran, M., Card, T. R., Aithal, G. P., Logan, R., & West, J. (2007). Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. Hepatology, 46(4), 1131-1137. https://doi.org/10.1002/hep.21795

There is debate over the mortality and malignancy risk in people with primary biliary cirrhosis (PBC) and whether this risk is reduced by use of ursodeoxycholic acid. To investigate this issue, we identified 930 people with PBC and 9,202 control subj... Read More about Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study.